The company Hospira and US Food and Drug Administration (FDA) have notified healthcare professional of a nationwide recall of certain injectable drug products, due to visible particles embedded in the glass located at the neck of the vial.
Hospira, Inc. is a provider of injectable drugs and infusion technologies.
The concern is that there may be potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution. In the event in which particulate matter could be injected into a patient, there may be the potential for patient injury where medical intervention may be required. Signs and symptoms might include bleeding, bruising, inflammation, itching, rash, chest pain and respiratory symptoms.
The drug products affected are: carboplatin, cytarabine, paclitaxel, and methotrexate.
For more details see FDA Medwatch